Induction of potent CD8+ T cell responses through the delivery of subunit protein vaccines to skin antigen-presenting cells using densely packed microprojection arrays

Journal of Controlled Release

Volumn 162, Issue 3, 2012, Pages 477-484

  Ng, Hwee Ing ^a   Fernando, Germain J P ^a   Kendall, Mark A F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adjuvant; CTL; Dose sparing; Microneedle; Needle free vaccine; Transdermal

Indexed keywords

ADJUVANT; CTL; DOSE SPARING; MICRONEEDLES; TRANSDERMAL;

ANTIBODIES; ANTIGENS; CELL CULTURE; CELL PROLIFERATION; CELLS; NEEDLES; VACCINES;

DISEASES;

CPG OLIGODEOXYNUCLEOTIDE; ENDOGRADE; OVALBUMIN; QUIL A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG COATING; DRUG DELIVERY SYSTEM; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SUBUNIT; SCANNING ELECTRON MICROSCOPY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; METHYLCELLULOSE; MICE; MICE, INBRED C57BL; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PROTEIN SUBUNITS; SAPONINS; SKIN; SPLEEN; TRANSDERMAL PATCH; VACCINATION; VACCINES, SUBUNIT;

EID: 84865539479     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.07.024     Document Type: Article

References (77)

1. P. Wong, and E.G. Pamer CD8 T Cell responses to infectious pathogens Annu. Rev. Immunol. 21 2003 29 70
2. K. Murali-Krishna, J.D. Altman, M. Suresh, D.J.D. Sourdive, A.J. Zajac, J.D. Miller, J. Slansky, and R. Ahmed Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection Immunity 8 1998 177 187
3. J.H.C.M. Kreijtz, R. Bodewes, G. van Amerongen, T. Kuiken, R.A.M. Fouchier, A.D.M.E. Osterhaus, and G.F. Rimmelzwaan Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice Vaccine 25 2007 612 620
4. W. Tu, H. Mao, J. Zheng, Y. Liu, S.S. Chiu, G. Qin, P.-L. Chan, K.-T. Lam, J. Guan, L. Zhang, Y. Guan, K.-Y. Yuen, J.S.M. Peiris, and Y.-L. Lau Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus J. Virol. 84 2010 6527 6535
5. P. Borrow, H. Lewicki, B.H. Hahn, G.M. Shaw, and M.B.A. Oldstone Virus specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type-1 infection J. Virol. 68 1994 6103 6110
6. D.H. Barouch Challenges in the development of an HIV-1 vaccine Nature 455 2008 613 619
7. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunotherapy: moving beyond current vaccines Nat. Med. 10 2004 909 915
8. C. Yee, J.A. Thompson, D. Byrd, S.R. Riddell, P. Roche, E. Celis, and P.D. Greenberg Adoptive T cell therapy using antigen-specific CD8(+) T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells Proc. Natl. Acad. Sci. U. S. A. 99 2002 16168 16173
9. K. Matsumoto, G.R. Leggatt, J. Zhong, X. Liu, R.L. de Kluyver, T. Peters, G.J. Fernando, A. Liem, P.F. Lambert, and I.H. Frazer Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors J. Natl. Cancer Inst. 96 2004 1611 1619
10. G.J. Fernando, V. Khammanivong, G.R. Leggatt, W.J. Liu, and I.H. Frazer The number of long-lasting functional memory CD8 + T cells generated depends on the nature of the initial nonspecific stimulation Eur. J. Immunol. 32 2002 1541 1549
11. F.G. Gao, V. Khammanivong, W.J. Liu, G.R. Leggatt, I.H. Frazer, and G.J.P. Fernando Antigen-specific CD4(+) T-cell help is required to activate a memory CD8(+) T cell to a fully functional tumor killer cell Cancer Res. 62 2002 6438 6441
12. J.L. Flynn, and J. Chan Immunology of tuberculosis Annu. Rev. Immunol. 19 2001 93 129
13. L. Schofield, J. Villaquiran, A. Ferreira, H. Schellekens, R. Nussenzweig, and V. Nussenzweig Gamma interferron, CD8 + T cells and antibodies required for immunity to malaria sporozoites Nature 330 1987 664 666
14. X.S. He, T.H. Holmes, C. Zhang, K. Mahmood, G.W. Kemble, D.B. Lewis, C.L. Dekker, H.B. Greenberg, and A.M. Arvin Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines J. Virol. 80 2006 11756 11766
15. J.E. Epstein, K. Tewari, K.E. Lyke, B.K.L. Sim, P.F. Billingsley, M.B. Laurens, A. Gunasekera, S. Chakravarty, E.R. James, M. Sedegah, A. Richman, S. Velmurugan, S. Reyes, M. Li, K. Tucker, A. Ahumada, A.J. Ruben, T. Li, R. Stafford, A.G. Eappen, C. Tamminga, J.W. Bennett, C.F. Ockenhouse, J.R. Murphy, J. Komisar, N. Thomas, M. Loyevsky, A. Birkett, C.V. Plowe, C. Loucq, R. Edelman, T.L. Richie, R.A. Seder, and S.L. Hoffman Live attenuated malaria vaccine designed to protect through hepatic CD8 + T cell immunity Science 334 2011 475 480
16. A.S. Kask, X. Chen, J.O. Marshak, L. Dong, M. Saracino, D. Chen, C. Jarrahian, M.A. Kendall, and D.M. Koelle DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge Vaccine 28 2010 7483 7491
17. H. Yu, L.A. Babiuk, and S. van Drunen Littel-van den Hurk Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3 J. Gen. Virol. 85 2004 1533 1543
18. M.A. Kutzler, and D.B. Weiner DNA vaccines: ready for prime time? Nat. Rev. Genet. 9 2008 776 788
19. R.M. Zinkernagel On natural and artificial vaccinations Annu. Rev. Immunol. 21 2003 515 546
20. M.M. Levine, and M.B. Sztein Vaccine development strategies for improving immunization: the role of modern immunology Nat. Immunol. 5 2004 460 464
21. M. Singh, and D. O'Hagan Advances in vaccine adjuvants Nat. Biotechnol. 17 1999 1075 1081
22. M.J. Newman, J.Y. Wu, B.H. Gardner, K.J. Munroe, D. Leombruno, J. Recchia, C.R. Kensil, and R.T. Coughlin Saponin adjuvant induction of ovalbumin-specific CD8 + cytotoxic lymphocyte T responses J. Immunol. 148 1992 2357 2362
23. G.J. Fernando, T.J. Stewart, R.W. Tindle, and I.H. Frazer Th2-type CD4 + cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model J. Immunol. 161 1998 2421 2427
24. G.J.P. Fernando, D.J. Stenzel, R.W. Tindle, M.S. Merza, B. Morein, and I.H. Frazer Peptide polymerization facilitates incorporation iscoms and increases antigen-specific IgG2a production Vaccine 13 1995 1460 1467
25. M.A.F. Kendall Needle-free vaccine injection Handb. Exp. Pharmacol. 2010 193 219
26. S. Mitragotri Immunization without needles Nat. Rev. Immunol. 5 2005 905 916
27. C. Gregor, and V. Ulrich Nanotechnology and the transdermal route: a state of the art review and critical appraisal J. Control. Release 141 2009 277 299
28. A. Arora, M.R. Prausnitz, and S. Mitragotri Micro-scale devices for transdermal drug delivery Int. J. Pharm. 364 2008 227 236
29. G. Cevc, and U. Vierl Nanotechnology and the transdermal route A state of the art review and critical appraisal J. Control. Release 141 2010 277 299
30. G. Widera, J. Johnson, L. Kim, L. Libiran, K. Nyam, P.E. Daddona, and M. Cormier Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system Vaccine 24 2006 1653 1664
31. J.B. Alarcon, A.W. Hartley, N.G. Harvey, and J.A. Mikszta Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines Clin. Vaccine Immunol. 14 2007 375 381
32. P. Van Damme, F. Oosterhuis-Kafeja, M. Van der Wielen, Y. Almagor, O. Sharon, and Y. Levin Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults Vaccine 27 2009 454 459
33. T.W. Prow, X. Chen, N.A. Prow, G.J.P. Fernando, C.S.E. Tan, A.P. Raphael, D. Chang, M.P. Ruutu, D.W.K. Jenkins, A. Pyke, M.L. Crichton, K. Raphaelli, L.Y.H. Goh, I.H. Frazer, M.S. Roberts, J. Gardner, A.A. Khromykh, A. Suhrbier, R.A. Hall, and M.A.F. Kendall Nanopatch-targeted skin vaccination against West Nile virus and Chikungunya virus in mice Small 6 2010 1776 1784
34. Y.-C. Kim, F.-S. Quan, R.W. Compans, S.-M. Kang, and M.R. Prausnitz Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity J. Control. Release 142 2010 187 195
35. X. Chen, A.S. Kask, M.L. Crichton, C. McNeilly, S. Yukiko, L. Dong, J.O. Marshak, C. Jarrahian, G.J.P. Fernando, D. Chen, D.M. Koelle, and M.A.F. Kendall Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays J. Control. Release 148 2010 327 333
36. G.J.P. Fernando, X. Chen, T.W. Prow, M.L. Crichton, E.J. Fairmaid, M.S. Roberts, I.H. Frazer, L.E. Brown, and M.A.F. Kendall Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model PLoS One 5 2010 e10266
37. X. Chen, H.J. Corbett, S.R. Yukiko, A.P. Raphael, E.J. Fairmaid, T.W. Prow, L.E. Brown, G.J.P. Fernando, and M.A.F. Kendall Site-selectively coated, densely-packed microprojection array patches for targeted delivery of vaccines to skin Adv. Funct. Mater. 21 2011 464 473
38. X. Chen, G.J.P. Fernando, M.L. Crichton, C. Flaim, S.R. Yukiko, E.J. Fairmaid, H.J. Corbett, C.A. Bover, A.B. Ansaldo, I.H. Frazer, L.E. Brown, and M.A.F. Kendall Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization J. Control. Release 152 2011 349 355
39. A.P. Raphael, T.W. Prow, M.L. Crichton, X. Chen, G.J.P. Fernando, and M.A.F. Kendall Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays Small 6 2010 1785 1793
40. X. Chen, G.J.P. Fernando, A.P. Raphael, S.R. Yukiko, E.J. Fairmaid, C.A. Primiero, I.H. Frazer, L.E. Brown, and M.A.F. Kendall Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin J. Control. Release 158 2012 78 84
41. H.J. Corbett, G.J.P. Fernando, X. Chen, I.H. Frazer, and M.A.F. Kendall Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model PLoS One 5 2010 e13460
42. G.J.P. Fernando, X. Chen, C.A. Primiero, S.R. Yukiko, E.J. Fairmaid, H.J. Corbett, I.H. Frazer, L.E. Brown, and M.A.F. Kendall Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses J. Control. Release 159 2012 215 221
43. M.L. Crichton, A. Ansaldo, X. Chen, T.W. Prow, G.J.P. Fernando, and M.A.F. Kendall The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine Biomaterials 31 2010 4562 4572
44. B. Deacon, and J. Abramowitz Fear of needles and vasovagal reactions among phlebotomy patients J. Anxiety Disord. 20 2006 946 960
45. M.D. Koch, H.K. O'Neill, C.N. Sawchuk, and K. Connolly Domain-specific and generalized disgust sensitivity in blood-injection-injury phobia: the application of behavioral approach/avoidance tasks J. Anxiety Disord. 16 2002 511 527
46. A. Prüss-Üstün, E. Rapiti, and Y. Hutin Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers Am. J. Ind. Med. 48 2005 482 490
47. Z.K. Ballas, A.M. Krieg, T. Warren, W. Rasmussen, H.L. Davis, M. Waldschmidt, and G.J. Weiner Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs J. Immunol. 167 2001 4878 4886
48. D. Jenkins, S. Corrie, C. Flaim, and M. Kendall High density and high aspect ratio solid micro-nanoprojection arrays for targeted skin vaccine delivery and specific antibody extraction Rsc Advances 2 2012 3490 3495
49. X. Chen, Tarl W. Prow, Michael L. Crichton, Germain J.P. Fernando, and M.A. Kendall Novel coating of Micro-nanoprojection patches for targeted vaccine delivery to skin ICONN 2008 2008 105 108
50. X. Chen, T.W. Prow, M.L. Crichton, D.W.K. Jenkins, M.S. Roberts, I.H. Frazer, G.J.P. Fernando, and M.A.F. Kendall Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin J. Control. Release 139 2009 212 220
51. F. Lechner, D.K.H. Wong, P.R. Dunbar, R. Chapman, R.T. Chung, P. Dohrenwend, G. Robbins, R. Phillips, P. Klenerman, and B.D. Walker Analysis of successful immune responses in persons infected with hepatitis C virus J. Exp. Med. 191 2000 1499 1512
52. S. Narayan, A. Choyce, G.J.P. Fernando, and G.R. Leggatt Secondary immunisation with high-dose heterologous peptide leads to CD8 T cell populations with reduced functional avidity Eur. J. Immunol. 37 2007 406 415
53. R.M. Coles, S.N. Mueller, W.R. Heath, F.R. Carbone, and A.G. Brooks Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1 J. Immunol. 168 2002 834 838
54. D.G. Koutsonanos, M. del Pilar Martin, V.G. Zarnitsyn, S.P. Sullivan, R.W. Compans, M.R. Prausnitz, and I. Skountzou Transdermal influenza immunization with vaccine-coated microneedle arrays PLoS One 4 2009 e4773
55. J. Watanabe, Y. Miyazaki, G.A. Zimmerman, K.H. Albertine, and T.M. McIntyre Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity J. Biol. Chem. 278 2003 42361 42368
56. K. Hoebe, and B. Beutler LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif Tram, and other TIR adaptor proteins Journal of Endotoxin Research 10 2004 130 136
57. B.J. Skidmore, J.M. Chiller, W.O. Weigle, R. Riblet, and J. Watson Immunologic properties of bacterial lipopolysaccharide (LPS). III. Genetic linkage between the in vitro mitogenic and in vivo adjuvant properties of LPS The Journal of Experimental Medicine 143 1976 143 150
58. H. Karch, and K. Nixdorff Modulation of the IgG subclass responses to lipopolysaccharide by bacterial-membrane components - differential adjuvant effects prodiced by primary and secondary stimulation J. Immunol. 131 1983 6 8
59. G.J.P. Fernando, T.J. Stewart, R.W. Tindle, and I.H. Frazer Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term Scand. J. Immunol. 47 1998 459 465
60. T. Liu, K.M. Khanna, X. Chen, D.J. Fink, and R.L. Hendricks CD8 + T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons The Journal of Experimental Medicine 191 2000 1459 1466
61. C.E. Mackewicz, H.W. Ortega, and J.A. Levy CD8 + cell anti-HIV activity correlates with the clinical state of the infected individual J. Clin. Invest. 87 1991 1462 1466
62. N. Castro-Díaz, B. Salaun, R. Perret, S. Sierro, J.F. Romero, J.-A. Fernández, A. Rubio-Moraga, and P. Romero Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines Vaccine 30 2012 388 397
63. G.P. Borja-Cabrera, A. Cruz Mendes, E. Paraguai de Souza, L.Y. Hashimoto Okada, A.T.F.A. de, J.K. Kawasaki, A.C. Costa, A.B. Reis, O. Genaro, L.M. Batista, M. Palatnik, and C.B. Palatnik-de-Sousa Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine Vaccine 22 2004 2234 2243
64. C.R. Kensil Saponins as vaccine adjuvants Crit. Rev. Ther. Drug Carrier Syst. 13 1996 1 55
65. G.B. Lipford, H. Wagner, and K. Heeg Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8 + cytotoxic T cells Vaccine 12 1994 73 80
66. K.J. Stittelaar, J. Boes, G.F.A. Kersten, A. Spiekstra, P.G.H. Mulder, P. de Vries, P.J.M. Roholl, K. Dalsgaard, G. van den Dobbelsteen, L. van Alphen, and A.D.M.E. Osterhaus In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components Vaccine 18 2000 2482 2493
67. M. Kim, H.-B. Moon, K. Kim, and K.-Y. Lee Antigen dose governs the shaping of CTL repertoires in vitro and in vivo Int. Immunol. 18 2006 435 444
68. D.E. Byers, and K.F. Lindahl Peptide affinity and concentration affect the sensitivity of M3-restricted CTLs induced in vitro J. Immunol. 163 1999 3022 3028
69. C.-A. Siegrist, M. Pihlgren, C. Tougne, S.M. Efler, M.L. Morris, M.J. AlAdhami, D.W. Cameron, C.L. Cooper, J. Heathcote, H.L. Davis, and P.-H. Lambert Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response Vaccine 23 2004 615 622
70. D.E. Speiser, D. Liénard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A.M. Krieg, J.-C. Cerottini, and P. Romero Rapid and strong human CD8 + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 J. Clin. Invest. 115 2005 739 746
71. S. Bauer, C.J. Kirschning, H. Häcker, V. Redecke, S. Hausmann, S. Akira, H. Wagner, and G.B. Lipford Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition Proc. Natl. Acad. Sci. 98 2001 9237 9242
72. D.M. Klinman, S. Klaschik, T. Sato, and D. Tross CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases Advanced Drug Delivery Reviews 61 2009 248 255
73. A.M. Krieg CpG motifs in bacterial DNA and their immune effects Annu. Rev. Immunol. 20 2002 709 760
74. K. Zhao, H. Wang, and C. Wu The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8 + T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848 Vaccine 29 2011 6670 6678
75. A. Iwasaki, and R. Medzhitov Regulation of adaptive immunity by the innate immune system Science 327 2010 291 295
76. S.A. Halperin, G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J.J. Eiden A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant Vaccine 21 2003 2461 2467
77. B.P. Sablan, D.J. Kim, N.G. Barzaga, W.C. Chow, M. Cho, S.H. Ahn, S.G. Hwang, J.H. Lee, H. Namini, and W.L. Heyward Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine Vaccine 30 2012 2689 2696